Guanhao Biotech Co Ltd
300238
Company Profile
Business description
Guanhao Biotech Co Ltd is a China-based biotech company. It develops, manufactures and markets life and health-related products, with focus on regenerative medicines for the treatment of damaged tissue and organs. Its products include NormalGEN dura repair patch, GrandNeuro (Type B) dura repair patch, ThromalGEN (Type P) surgical patch, Guanhao-ACI, among others.
Contact
No.12 Yuyan Road
Luogang District, Guangdong
Guangzhou510530
CHNT: +86 2032052295
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
530
Stocks News & Analysis
stocks
Finding yield on the ASX
The ASX, known for its yield appeal is at its lowest level in 20 years. Here’s why, and what investors should do.
stocks
ExxonMobil earnings: Continued execution, on track for 2030 targets
We’ve raised our fair value estimate of Exxon stock.
stocks
Disney earnings: No big surprises in solid results
Growth in areas critical to the firm’s future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,068.80 | 42.20 | -0.46% |
| CAC 40 | 8,181.17 | 54.64 | 0.67% |
| DAX 40 | 24,797.52 | 258.71 | 1.05% |
| Dow JONES (US) | 49,407.66 | 515.19 | 1.05% |
| FTSE 100 | 10,341.56 | 118.02 | 1.15% |
| HKSE | 26,775.57 | 611.54 | -2.23% |
| NASDAQ | 23,592.11 | 130.29 | 0.56% |
| Nikkei 225 | 52,655.18 | 667.67 | -1.25% |
| NZX 50 Index | 13,443.27 | 30.83 | 0.23% |
| S&P 500 | 6,976.44 | 37.41 | 0.54% |
| S&P/ASX 200 | 8,778.60 | 42.50 | -0.48% |
| SSE Composite Index | 4,015.75 | 102.20 | -2.48% |